AMO Pharma Wraps Up FDA Consultation, Reveals Strategy for Advancing AMO-02 (tideglusib) in Myotonic Dystrophy Therapy
Friday, May 03, 2024
AMO Pharma Limited, a company specializing in rare genetic disorders, has shared updates on its plans for advancing the development of AMO-02 (tideglusib) to treat Type 1 myotonic dystrophy (DM1) following discussions with the U.S. Food and Drug Administration (FDA). Based on the FDA's feedback, AMO Pharma will proceed with a Phase 3 clinical trial targeting adult patients with adult-onset DM1, aiming to support future approval for DM1 treatment across all age groups.
The decision follows insights gained from AMO Pharma's previous REACH-CDM Phase 2/3 clinical study, which focused on children and adolescents with congenital-onset DM1. While the study demonstrated the safety and tolerability of AMO-02, unexpected placebo effects obscured some treatment benefits. However, further analysis, conducted in consultation with the FDA, has provided evidence supporting the continued development of tideglusib for DM1, leading to the decision to advance to a Phase 3 trial in adults with adult-onset DM1.
The FDA reviewed data from the REACH-CDM Study and provided guidance on the design of the upcoming Phase 3 trial, which will assess efficacy and safety measures similar to those used in the previous study. AMO Pharma plans to combine data from this new trial with findings from the REACH-CDM Study to support a future submission for approval of AMO-02 in children, adolescents, and adults with DM1.
AMO Pharma, expressed satisfaction with the FDA discussions and emphasized the company's commitment to advancing treatment options for DM1 patients. Hanns Lochmuller, an investigator in the REACH-CDM Study, echoed this sentiment, expressing optimism about the potential impact of AMO-02 on patients' health.
AMO-02, an investigational therapy, targets DM1 through a dual mechanism, disrupting pathogenic RNA repeats and inhibiting excess levels of the kinase GSK3β.
The REACH-CDM Study was a double-blind, placebo-controlled trial involving children and adolescents with congenital DM1. Post-hoc analysis revealed positive responses to AMO-02 treatment across various measures, including motor function, cognition, and adaptive behavior. These findings underscore the potential of AMO-02 to address the complex symptoms of DM1.
In summary, AMO Pharma's collaboration with the FDA and the promising results from the REACH-CDM Study lay a solid foundation for advancing the development of AMO-02 as a treatment for DM1 across different age groups, offering hope to patients living with this rare and debilitating condition.
Source: prnewswire.com
